Home > Drugs A-Z > Terrell

Terrell (Piramal Critical Care Inc.)

Available Formats

Dosage Form Package Information Links
INHALANT 100 mL in 1 BOTTLE, GLASS (66794-011-10) Label Information
INHALANT 250 mL in 1 BOTTLE, GLASS (66794-011-25) Label Information

Complete Terrell Information


    Terrell (isoflurane, USP), a nonflammable liquid administered by vaporizing, is a general inhalation anesthetic drug. It is 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether, and its structural formula is:  


    Some physical constants are:  
    Molecular weight                                  184.5
    Boiling point at 760 mm Hg                 48.5° C (uncorr.)
    Refractive index                                   1.2990-1.3005
    Specific gravity 25°/25° C                    1.496
    Vapor pressure in mm Hg** 20° C       238  
                                                  25° C       295  
                                                  30° C       367  
                                                  35° C       450  

    **Equation for vapor pressure calculation:   log10Pvap = A + B/T
    A = 8.056
    B = -1664.58
    T = ° C + 273.16 (Kelvin)  

    Partition coefficients at 37° C:      
    Water/gas      0.61  
    Blood/gas      1.43  
    Oil/gas           90.8 

    Partition coefficients at 25° C - rubber and plastic  
    Conductive rubber/gas      62.0  
    Butyl rubber/gas               75.0  
    Polyvinyl chloride/gas      110.0  
    Polyethylene/gas               ~2.0  
    Polyurethane/gas               ~1.4  
    Polyolefin/gas                    ~1.1  
    Butyl acetate/gas               ~2.5

    Purity by gas chromatography           >99.9%    

    Lower limit of flammability in oxygen or nitrous oxide at 9 joules/sec. and 23° C                  None    

    Lower limit of flammability in oxygen or nitrous oxide at 900 joules/sec. and 23° C              Greater than useful concentration in anesthesia. 

    Isoflurane is a clear, colorless, stable liquid containing no additives or chemical stabilizers. Isoflurane has a mildly pungent, musty, ethereal odor. Samples stored in indirect sunlight in clear, colorless glass for five years, as well as samples directly exposed for 30 hours to a 2 amp, 115 volt, 60 cycle long wave U.V. light were unchanged in composition as determined by gas chromatography. Isoflurane in one normal sodium methoxide-methanol solution, a strong base, for over six months consumed essentially no alkali, indicative of strong base stability. Isoflurane does not decompose in the presence of soda lime (at normal operating temperatures), and does not attack aluminium, tin, brass, iron or copper.


    Isoflurane is an inhalation anesthetic. The MAC (minimum alveolar concentration) in man is as follows:

     Age 100% Oxygen
    70% N2O

     26 ± 4



     44 ± 7



     64 ± 5



    Induction of and recovery from isoflurane anesthesia are rapid. Isoflurane has a mild pungency, which limits the rate of induction, although excessive salivation or tracheobronchial secretions do not appear to be stimulated. Pharyngeal and laryngeal reflexes are readily obtunded. The level of anesthesia may be changed rapidly with isoflurane. Isoflurane is a profound respiratory depressant. RESPIRATION MUST BE MONITORED CLOSELY AND SUPPORTED WHEN NECESSARY.   As anesthetic dose is increased, tidal volume decreases and respiratory rate is unchanged. This depression is partially reversed by surgical stimulation, even at deeper levels of anesthesia. Isoflurane evokes a sigh response reminiscent of that seen with diethyl ether and enflurane, although the frequency is less than with enflurane.  

    Blood pressure decreases with induction of anesthesia but returns toward normal with surgical stimulation. Progressive increases in depth of anesthesia produce corresponding decreases in blood pressure. Nitrous oxide diminishes the inspiratory concentration of isoflurane required to reach a desired level of anesthesia and may reduce the arterial hypotension seen with isoflurane alone. Heart rhythm is remarkably stable. With controlled ventilation and normal PaCO2, cardiac output is maintained despite increasing depth of anesthesia, primarily through an increase in heart rate, which compensates for a reduction in stroke volume. The hypercapnia, which attends spontaneous ventilation during isoflurane anesthesia further increases heart rate and raises cardiac output above awake levels. Isoflurane does not sensitize the myocardium to exogenously administered epinephrine in the dog. Limited data indicate that subcutaneous injection of 0.25 mg of epinephrine (50 mL of 1:200,000 solution) does not produce an increase in ventricular arrhythmias in patients anesthetized with isoflurane.  

    Muscle relaxation is often adequate for intra-abdominal operations at normal levels of anesthesia.  Complete muscle paralysis can be attained with small doses of muscle relaxants. ALL COMMONLY USED MUSCLE RELAXANTS ARE MARKEDLY POTENTIATED WITH ISOFLURANE, THE EFFECT BEING MOST PROFOUND WITH THE NONDEPOLARIZING TYPE. Neostigmine reverses the effect of nondepolarizing muscle relaxants in the presence of isoflurane. All commonly used muscle relaxants are compatible with isoflurane.  

    Isoflurane can produce coronary vasodilation at the arteriolar level in selected animal models1,2; the drug is probably also a coronary dilator in humans. Isoflurane, like some other coronary arteriolar dilators, has been shown to divert blood from collateral dependent myocardium to normally perfused areas in an animal model (“coronary steal”)3. Clinical studies to date evaluating myocardial ischemia, infarction and death as outcome parameters have not established that the coronary arteriolar dilation property of isoflurane is associated with coronary steal or myocardial ischemia in patients with coronary artery disease4,5,6,7.

    Isoflurane undergoes minimal biotransformation in man. In the postanesthesia period, only 0.17% of the isoflurane taken up can be recovered as urinary metabolites.


    Isoflurane may be used forinduction and maintenance of general anesthesia. Adequate data have notbeen developed to establish its application in obstetrical anesthesia.


    Known sensitivity to isoflurane or to other halogenated agents. Known or suspected genetic susceptibility to malignant hyperthermia.


    Perioperative Hyperkalemia

    Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period. Patient with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatinine kinase levels and, in some cases, changes in urine consistent with myoglobinuria. Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state. Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease.

    Malignant Hyperthermia

    In susceptible individuals, isoflurane anesthesia may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia. The syndrome includes nonspecific features such as muscle rigidity, tachycardia, tachypnea, cyanosis, arrhythmias, and unstable blood pressure. (It should also be noted that many of these nonspecific signs may appear with light anesthesia, acute hypoxia, etc.) An increase in overall metabolism may be reflected in an elevated temperature (which may rise rapidly early or late in the case, but usually is not the first sign of augmented metabolism) and an increased usage of the CO2 absorption system (hot canister). PaO2 and pH may decrease, and hyperkalemia and a base deficit may appear. Treatment includes discontinuance of triggering agents (e.g., isoflurane), administration of intravenous dantrolene sodium, and application of supportive therapy. Such therapy includes vigorous efforts to restore body temperature to normal, respiratory and circulatory support as indicated, and management of electrolyte-fluid-acid-base derangements. (Consult prescribing information for dantrolene sodium intravenous for additional information on patient management.) Renal failure may appear later, and urine flow should be sustained if possible.

    Since levels of anesthesia may be altered easily and rapidly, only vaporizers producing predictable concentrations should be used. Hypotension and respiratory depression increase as anesthesia is deepened.

    Increased blood loss comparable to that seen with halothane has been observed in patients undergoing abortions.

    Isoflurane markedly increases cerebral blood flow at deeper levels of anesthesia. There may be a transient rise in cerebral spinal fluid pressure, which is fully reversible with hyperventilation.



    As with any potent general anesthetic, isoflurane should only be administered in an adequately equipped anesthetizing environment by those who are familiar with the pharmacology of the drug and qualified by training and experience to manage the anesthetized patient.

    Regardless of the anesthetics employed, maintenance of normal hemodynamics is important to the avoidance of myocardial ischemia in patients with coronary artery disease4,5,6,7.

    Isoflurane, like some other inhalational anesthetics, can react with desiccated carbon dioxide (CO2) absorbents to produce carbon monoxide, which may result in elevated levels of carboxyhemoglobin in some patients. Case reports suggest that barium hydroxide lime and soda lime become desiccated when fresh gases are passed through the CO2 absorber canister at high flow rates over many hours or days. When a clinician suspects that CO2 absorbent may be desiccated, it should be replaced before the administration of isoflurane.

    As with other halogenated anesthetic agents, Isoflurane may cause sensitivity hepatitis in patients who have been sensitized by previous exposure to halogenated anesthetics (see CONTRAINDICATIONS).


    Isoflurane, as well asother general anesthetics, may cause a slight decrease in intellectual functionfor 2 or 3 days following anesthesia. As with other anesthetics, small changesin moods and symptoms may persist for up to 6 days after administration.


    Transient increases in BSPretention, blood glucose and serum creatinine with decrease in BUN, serumcholesterol and alkaline phosphatase have been observed.


    Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N2O. (See CLINICAL PHARMACOLOGY).


    Swiss ICR mice were givenisoflurane to determine whether such exposure might induce neoplasia.Isoflurane was given at 1/2, 1/8 and 1/32 MAC for four in-utero exposures andfor 24 exposures to the pups during the first nine weeks of life. The mice werekilled at 15 months of age. The incidence of tumors in these mice was the sameas in untreated control mice, which were given the same background gases, butnot the anesthetic.


    PregnancyCategory C

    Isoflurane has been shown to have a possible anesthetic-relatedfetotoxic effect in mice when given in doses 6 times the human dose. There areno adequate and well-controlled studies in pregnant women. Isoflurane should beused during pregnancy only if the potential benefit justifies the potentialrisk to the fetus.


    It is not known whetherthis drug is excreted in human milk. Because many drugs are excreted in humanmilk, caution should be exercised when isoflurane is administered to a nursingwoman.


    Adverse reactions encountered in the administration of isoflurane are in general dose dependent extensions of pharmacophysiologic effects and include respiratory depression, hypotension and arrhythmias.

    Shivering, nausea, vomiting and ileus have been observed in the postoperative period.

    As with all other general anesthetics, transient elevations in white blood count have been observed even in the absence of surgical stress. See WARNINGS for information regarding malignant hyperthermia and elevated carboxyhemoglobin levels.

    During marketing, there have been rare reports of mild, moderate and severe (some fatal) postoperative hepatic dysfunction and hepatitis.

    Isoflurane has also been associated with perioperative hyperkalemia (see WARNINGS).


    Post-Marketing Events:
    The following adverse events have been identified during post-approval use of isoflurane. Due to the spontaneous nature of these reports, the actual incidence and relationship of isoflurane, these events cannot be established with certainty.

    Cardiac Disorders: Cardiac arrest

    Hepatobiliary Disorders: Hepatic necrosis, Hepatic failure


    In the event ofoverdosage, or what may appear to be overdosage, the following action should betaken:

    Stop drug administration, establish a clear airway and initiate assistedor controlled ventilation with pure oxygen.



    Premedication shouldbe selected according to the need of the individual patient, taking intoaccount that secretions are weakly stimulated by isoflurane, and the heart ratetends to be increased. The use of anticholinergic drugs is a matter of choice.


    The concentration ofisoflurane being delivered from a vaporizer during anesthesia should be known.

    This may beaccomplished by using:

    a) vaporizerscalibrated specifically for isoflurane;

    b) vaporizers fromwhich delivered flows can be calculated, such as vaporizers delivering asaturated vapor which is then diluted. The delivered concentration from such avaporizer may be calculated using the formula:

    % Isoflurane =  100 PVFV

                            FT (PA– PV)


    PA =Pressure of atmosphere

    PV = Vaporpressure of isoflurane

    FV = Flowof gas through vaporizer (mL/min)

    FT = Totalgas flow (mL/min)

    Isoflurane containsno stabilizer. Nothing in the agent alters calibration or operation of these vaporizers.


    Induction withisoflurane in oxygen or in combination with oxygen-nitrous oxide mixtures mayproduce coughing, breath holding, or laryngospasm. These difficulties may beavoided by the use of a hypnotic dose of an ultra-short-acting barbiturate.Inspired concentrations of 1.5 to 3.0% isoflurane usually produce surgicalanesthesia in 7 to 10 minutes.


    Surgical levels ofanesthesia may be sustained with a 1.0 to 2.5% concentration when nitrous oxideis used concomitantly. An additional 0.5 to 1.0% may be required whenisoflurane is given using oxygen alone. If added relaxation is required,supplemental doses of muscle relaxants may be used.

    The level of blood pressure during maintenance is an inverse function ofisoflurane concentration in the absence of other complicating problems.Excessive decreases may be due to depth of anesthesia and in such instances maybe corrected by lightening anesthesia.


    Terrell (isoflurane, USP) is packaged in 100 mL and 250 mL amber-colored bottles.

    100 ML - NDC 66794-011-10

    250 ML - NDC 66794-011-25

  • Safety and Handling

    Occupational Caution

    There is no specificwork exposure limit established for Isoflurane. However, the National Institutefor Occupational Safety and Health Administration (NIOSH) recommends that noworker should be exposed at ceiling concentrations greater than 2ppm of anyhalogenated anesthetic agent over a sampling period not to exceed one hour.

    The predicted effects of acute overexposure by inhalation of Isofluraneinclude headache, dizziness or (in extreme cases) unconsciousness. There are nodocumented adverse effects of chronic exposure to halogenated anesthetic vapors(Waste Anesthetic Gases or WAGs) in the workplace.Although results of some epidemiological studies suggest a link betweenexposure to halogenated anesthetics and increased health problems (particularlyspontaneous abortion), the relationship is not conclusive. Since exposure toWAGs is one possible factor in the findings for these studies, operating roompersonnel, and pregnant women in particular, should minimize exposure.Precautions include adequate general ventilation in the operating room, the useof a well-designed and well-maintained scavenging system, work practices tominimize leaks and spills while the anesthetic agent is in use, and routineequipment maintenance to minimize leaks.

  • Storage

    Store at room temperature15 ° to 30°C (59 to 86°F). Isoflurane, contains noadditives and has been demonstrated to be stable at room temperature forperiods in excess of five years.


    1. J.C. Sill, et al, Anesthesiology 66:273-279, 1987
    2. R.F. Hickey, et al, Anesthesiology 68:21-30, 1988
    3. C.W. Buffington, et a l, Anesthesiology 66:280-292, 1987
    4. S. Reiz, et al, Anesthesiology 59:91-97, 1983
    5. S. Slogoff and A.S. Keats , Anesthesiology 70:179-188, 1989
    6. K.J. Tuman, et al, Anesthesiology 70:189-198, 1989
    7. D.T. Mangano, Editorial Views, Anesthesiology 70:175-178, 1989

  • Manufacturer

    Manufactured By:

    Piramal Critical Care, Inc.

    3950 Schelden Circle

    Bethlehem, PA 18017

    (888) 822-8431

    © 2014 Piramal Critical Care, Inc.




  • Principal Display Panel


    isoflurane liquid
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:66794-011
    Route of Administration RESPIRATORY (INHALATION)
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:66794-011-10 100 mL in 1 BOTTLE, GLASS
    2 NDC:66794-011-25 250 mL in 1 BOTTLE, GLASS
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA074416 01/01/2010
    Labeler - Piramal Critical Care Inc (805600439)
    Name Address ID/FEI Business Operations
    Piramal Critical Care Inc 805600439 ANALYSIS(66794-011) , API MANUFACTURE(66794-011) , LABEL(66794-011) , MANUFACTURE(66794-011) , PACK(66794-011)